Jamaeel W. – Pediatric Stroke After Oxbryta Treatment

Background

Jamaeel W., a 14-year-old honor student from Chicago, was prescribed Oxbryta in 2023 after his sickle cell disease (SCD) symptoms worsened. His hematologist assured the family the drug was "FDA-approved and life-changing." Within 5 months, Jamaeel suffered a massive ischemic stroke that left him with right-sided paralysis and speech impairment.

Medical Impact

• Acute Stroke: MRI confirmed blockage in left middle cerebral artery
• Long-Term Disabilities:
  • Permanent weakness in dominant right hand (ending piano scholarship hopes)
  • Expressive aphasia requiring speech therapy 3x/week
  • Emotional lability and depression
• Additional Complications:
  • Hospital records showed hemoglobin dropped to 5.2 g/dL post-stroke
  • Developed seizures requiring anti-epileptic drugs

Initial Obstacles

1. Pfizer claimed the stroke was "unrelated" to Oxbryta despite timing
2. Insurance denied coverage for experimental rehab therapies
3. School district resisted accommodating new disabilities

How Injurease Intervened

• Connected family with a pediatric neurology expert who linked stroke to Oxbryta-induced blood viscosity changes
• Partnered with a firm that subpoenaed Pfizer’s internal safety reports showing 8 pediatric deaths in clinical trials
• Arranged pro bono neuropsychological testing to quantify cognitive losses
• Negotiated with school for IEP accommodations during case proceedings

Legal Strategy

• Focused on:
  1. Failure to Warn: Proved Pfizer knew stroke risks from GBT440-032 trial but didn’t update labeling
  2. Negligent Marketing: Showed promotional materials overstated benefits to minority communities
  3. Future Costs: Life care plan projected $4.3M in lifetime expenses

Outcome

• $2.1M settlement (2025) covering:
  • $850K future medical/rehab
  • $300K lost scholarship value
  • $950K pain/suffering
• Additional concessions:
  • Pfizer-funded vocational training program
  • Apology letter from medical director

Jamaeel’s Mother’s Words:
"They said Oxbryta would help him thrive. Instead, it stole his voice and his future. Injurease gave us the resources to fight back when everyone else looked away."

[fluentform_modal form_id="12" btn_text="Click to Start Case Evaluation"]